News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Echosens: A Highly Representative FibroScan(R) Presence at the GASL Congress Bonn, January 29-30th, 2010



2/4/2010 12:42:36 PM

PARIS, FRANCE--(Marketwire - February 04, 2010) - The Echosens™ Company that develops and manufactures the FibroScan® was strongly represented at Bonn during the GASL, January 29-30th with a booth but even more by doctors' Publications.

This growing numbers of posters and communications demonstrate the interest of the doctors for this tool.

FibroScan® is today a clinically validated tool with more than 250 independent publications and 300 communications worldwide.

This unique piece of equipment powered by VCTE™ applies on chronic liver diseases with a large spectrum of actions from diagnosis, monitoring to predictions of complications.

German teams have strongly contributed to establish this with highly interesting meta-analysis1 and validation of the new XL Probe.

This technology differs from other elastography technique with an unmatched reproducibility corroborated by clinical data.

Echosens: Partner for diagnostic solutions in Hepatology

A French company founded in 2001 in Paris, Echosens is an international SME specializing in the field of hepatology. Echosens has a network of 3 subsidiaries that have been set up in strategic areas in Europe and Asia. Currently, these subsidiaries in Germany and Spain as well as China provide EchoSens with greater proximity to its clients.

The company developed and manufactures the FibroScan® device, based on VCTE™ "Vibration Controlled Transcient Elastography". Echosens has changed hepatologists' clinical practices by making available to them a new tool for diagnosis and follow-up of liver diseases. Echosens dedicates a significant part of its activity to Research in order to develop new medical devices and to open up new medical perspectives. The company works in close cooperation with health professionals and patients' associations to facilitate therapeutic follow up of patients. To date, 645 FibroScan® devices have been installed worldwide, including 157 in France. HAS (Health French authority) validated the Fibroscan® for the diagnosis of HCV and HIV-HCV

For more information: www.echosens.com

Press kit available on demand

1 - Friedrich-Rust, M., M.F. Ong, S. Martens, et al., Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134(4):960-74.


Contacts:
Cecile Guiducci
International Marketing Director
+33 1 44 82 78 50
communication@echosens.com
www.echosens.com

Echosens Deutschland GmbH
+49 (0) 172 4008057
+49 (0) 2225 18476


Read at BioSpace.com


comments powered by Disqus
Echosens
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES